Appropriate dosage selection is a key element in the design of toxicology studies and, hence, is the first step in the process of evaluating the safety of a new chemical or pharmaceutical agent. This demands careful consideration of exposure to the drug or chemical under investigation in relation to the pharmacological or toxicological effects it evokes in an experimental animal. Toxicokinetic data provide this perspective, but they should not be considered exclusively of other data which reflect the specific activity, potency, or metabolism of the drug or chemical in each individual test species. It is equally inappropriate to base dosage 'selection in toxicology studies exclusively on functional or morphological endpoints that cause effects outside the range which can be accommodated by homeostatic mechanisms and repair processes. Finally, extrapolation of toxicokinetic data across species lines can lead to serious miscalculations with respect to both dosage selection and the process of risk assessment. In each case, decisions should be based on the integration of toxicokinetic data with other measures and endpoints of biological and toxicological effect.
INTRODUCTION
Toxicokinetics is a composite term for the characterization of the exposure of a test animal to a drug or chemical at doses which elicit a toxic response. Typically, toxicokinetic data are obtained by analysis of blood or plasma samples taken sequentially from test animals during the course of exposure to different dosages of a drug or chemical (6; 14) . Knowledge of toxicokinetics is not obligatory for evaluating toxicity or for selecting dosages to be administered to animals in toxicology studies. The toxicity of many drugs and chemicals has been well characterized for more than a century by noting their effects on the behavior and survival of test animals and by observing changes in organ function and morphology. The additive value of toxicokinetic data derives from the fact that knowledge of the amount ofdrug and the'manner in which it exists in the test animal during a given interval permits a more meaningful correlation between dosage and the toxic effects observed. This additional refinement also enables us to evaluate the quantitative and qualitative significance of the toxic effects observed and their potential relationship to the concentration of drug or chemical in the blood.
.. There is a broad consensus among toxicologists and their colleagues in the field of drug metabolism fh'at knowledge of toxicokinetics adds a valuable perspective to the interpretation of observations made in toxicology studies. Indeed, in many instances, toxicokinetic data contribute to the elucidation of mechanisms underlying the toxic effects produced by drugs or chemicals. However, this general agreement stands in marked contrast to the difference of opinion about the application of toxicokinetic data to dosage selection in toxicology studies. The most contentious debate centers around selectionof the highest dosage to be used in a toxicology study (4, 10, 18). On one side of the debate are those who argue that clinical and pathological endpoints should be the sole criterion used for selection of the highest dosage, without consideration being given to toxicokinetic data. This, they claim, is the most appropriate approach to determining the toxic potential of a new chemical entity and thus to assess its safety. On the other side are those who argue that a dosage that saturates absorption, metabolism, or excretion of a compound is inappropriate because it results in atypical exposure of the test species, which is of no relevance to the exposure in human patients receiving the drug at therapeutic dosages. This, they claim, renders toxicity data generated under these conditions of little value to risk assessment. There is merit in each of these arguments, but the prudent approach to dosage selection in toxicology studies is one that is cognizant of both when considering dosage selection for toxicity studies. The toxicologist in the field of drug development is presented with complex chemicals possessing a diverse array of pharmacologic activities and is, therefore, challenged to integrate toxicokinetic data with clinical and pathological measures of toxicity. Also to be considered are the physical, chemical, and therapeutic attributes of the drug under investigation and the patient population to whom it will be prescribed.
This paper will attempt to illustrate in practical terms how toxicokinetic data can be utilized in drug development for the purpose of dosage selection in toxicology studies. Case studies will be presented in which toxicokinetic data contributed to dosage selection, study design, the interpretation of toxicology data, and the safety assessment of the drug under investigation.
DOSAGE SELECTION IN ToXrCoLoGY STUDIES-GENERAL PRINCIPLES Acute atid Strbchronic Studies
Toxicology studies conducted before the first introduction of a new drug into humans (Phase I studies) are designed to reveal its full toxic potential in animals. Studies of relatively short duration (single dose or daily dosing up to 10 days) using small groups of animals, exposed to a wide range of dosages, are conducted initially to determine the broad nature and extent ofthe toxic response. These initial observations guide dosage selection in subsequeGt. studies, usually of 1 mo duration, which are completed prior to initiating Phase I studies. Toxicokinetic data may influence the range-of dosages employed in these studies but, generally, do not place a limit on the highest dosage. Selection ofthe highest dosage in these studies is usually based on combinations of clinical, functional, or pathological endpoints, or limitations of the formulation. The concentration of the drug, and occasionally its principal and/or active metabolite(s), in blood or plasma of test animals may be determined in range-finding studies and usually on the first and last days of the 1-mo study. These data provide useful information about the rate of absorption, the peak plasma concentration achieved ((&), the time taken after dosing to reach C, , , (T,,,), the half-life during the elimination phase, the area under the concentrationtime curve (AUC), and the potential for changes in pharmacokinetics of the parent drug or its metabolites in the test animal upon repeated dosing (e.g., accumulation, auto-induction). A less than proportional increase between the oral dosage given and the resultant plasma concentration would suggest that systemic exposure may be limited by absorption. Alternatively a more than proportional increase may suggest saturation of elimination or firstpass metabolism. Toxicokinetic data may reveal a temporal relationship between plasma concentration and toxic response. Although toxicokinetic data make only a minor contribution to dosage selection in toxicology studies in these early stages of drug development, they add another dimension to the interpretation of the toxic response manifested by the test anim.al, aid in the design of chronic toxicology studies, and in establishing safe starting dosages for Phase I studies in human subjects.
Chronic Toxicity Studies
Chronic toxicity studies of 6 or 12 mo duration in rodent and nonrodent species and lifetime carcinogenicity studies in 2-rodent species are conducted to support studies in Phase I1 and Phase I11 of clinical development. It is a common misconception that these animal studies must play a pivotal role in determining the dosages administered to human patients. They do not necessarily, although from time to time justification is needed to gain approval for a human dosage that is likely to result in plasma concentrritions equivalent to, or greater than, those achieved in earlier animal studies.
At this stage of drug development, exposure data hbtained from acute and subchronic studies in animals, and pharmacokinetic data from Phase I and Phase I1 studies in humans, should guide dosage selection as well as the design of chronic toxicity studies in animals. For example, the choice of drug formulation, the route of administration, the frequency of daily dosing, and the dosing regimen in relation to feeding may be adjusted in the animal studies to simulate the pattern of human exposure to the drug under therapeutic conditions. Although the design of toxicology studies can be manipulated in these different ways to achieve similar patterns of exposure in the test animals relative to human patients, it is virtually impossible to prescribe in advance a high dosage to the animal species that % .. <. . at SAGE PUBLICATIONS on December 9, 2012 tpx.sagepub.com Downloaded from TOXICOLOGIC PATHOLOGY will achieve particular multiples of the human therapeutic C,,, and/or AUC. Experience tells us that the vast majority of drugs tested in preclinical development do not yield AUC values at the highest dosage in animals that are more than 5-to 10-fold the human AUC and, in some cases, this multiple is less than 1. .
There are numerous examples where a retrospective analysis of pharmacokinetic and physiologic data obtained from comparative studies in humans and animals has resulted in recommendations to restrict exposure to industrial chemicals within limits deemed to be safe (1, 8, 15) . However, the toxicologist engaged in drug development is rarely able to apply such data prospectively to therapeutic agents and is, therefore, unable to set animal exposure at some predetermined multiple of the putative exposure in humans with the objective of achieving safety margins acceptable in advance to clinical and regulatory colleagues. The amount of quantitative data available concerning absorption, disposition, metabolism, and elimination of a new drug in humans is frequently scant when chronic toxicity studies are scheduled to start. The toxicologist in drug development is compelled, therefore, to apply toxicokinetic data in a semiquantitative manner for the purpose of dosage selection in toxicology studies. As a general rule, the highest dosage selected for a chronic toxicity study should not elicit changes in major organ function that are not restored quickly to within normal bounds by compensatory homeostatic mechanisms after administration ofeach dose. Also, it should not give rise to excessive dose-dependent changes in absorption, disposition, metabolism, and elimination (ADME) of the drug. Hence, it should be possible to select a high dosage that produces only minor deviations in organ function and transient and reversible changes in cellular physiology. Organ damage, detectable morphologically and manifest as tissue necrosis, should be avoided. This upper limit on the high dosage often falls significantly below the maximally tolerated dose in an acute or subchronic study which, in a chronic study, would cause organ damage and potentially life-threatening toxicity.
.. APPLICATION OF TOXICOKINETIC DATA TO DOSAGE SELECTION Within the framework of the general principles already outlined, toxicokinetic data can provide a useful guide to dosage selection provided consid: eration is given to the entire spectrum of drug-induced toxicity and an attempt is made to relate each toxic manifestation to the most appropriate and concurrent measure of exposure. Toxicity may represent a continuum of events, one toxic manifes-tation leading to another, as depicted in Fig. 1 . Alternatively, toxicity may result from the coincidence or superimposition ofrdiscrete and discontinuous events. In the latter case, each manifestation of toxicity may have a different mechanistic and toxicokinetic basis. For the purpose of dosage selection, each toxic manifestation should be analyzed separately and a correlation sought between each measure of exposure that best reflects the pathogenesis and mechanism of the related toxic effect. In practice, dosage selection, then, becomes a trade-off wherein the high dosage may have to be restricted so that pharmacologically mediated toxicity in a particular organ system at one level of exposure is not allowed to compromise the function of another organ system or radically increase (or decrease) the amount of drug that otherwise would be delivered to it. It is not uncommon for toxicity in one organ to result in atypical exposure of another organ, thus producing secondary effects that are not a true reflection of the drug's innate toxicity. For example, cardioactive and vasoactive drugs can alter renal hemodynamics in a manner that renders the kidney more vulnerable to toxic injury than would otherwise be the case. Kidney damage may result from simple ischemia produced by renal vasoconstriction, or systemic hypotension, or reduced cardiac output. Anemia may result in centrilobular hepatic necrosis. Increased renal blood flow produced by increased cardiac output, o r reduced renal vascular resistance, may increase exposure of the kidney overall to the drug or its metabolites. Similarly, enhanced clearance of the drug or its metabolites by increased glomerular filtration and/or tubular secretion would greatly increase exposure of renal tubular cells and distal parts of the urinary tract to toxic drug products. Clearly, if exposure levels causing such secondary perturbations of organ function, and hence toxicity, at high dosages in an animal species do not relate to the pharmaco-disposition and toxic potential ofthe drug at therapeutic dosages in humans, the utility of the animal data in safety evaluation and human risk assessment is seriously undermined.
In the case of drugs which exert reversible pharinacodynamic esfects, rapid in onset and short-lasting, C,,, is often the most relevant measure of effective exposure (2,11,12). Since pharmacologically mediated toxicity is also dependent on the rate of exposure, and in particular the rate at which the maximum plasma concentration is attained, this kind of toxicity can be modulated by changing the drug formulation or the mode of administration. exposure over the duration of the dosing interval (12) .
Toxicity in organs of metabolism and clearance, the liver and kidney, for example, may be related to the AUC, although this parameter does not directly indicate the concentration of drug or metabolites at the site of toxicity (e.g., in renal tubules or bile ducts). It is clearly not logical to use dosages that saturate clearance mechanisms, thus causing progressive damage to these organs of excretion.
Toxicity from saturation of excretory processes is compounded in chronic studies by the fact that the clearance capacity of excretory organs may be further diminished as a result of spontaneous disease in aging animals. Spontaneous disease may exacerbate toxicity in excretory organs while, at the same time, progressively increasing systemic exposure to the drug or its metabolites in a highly variable and uncontrollable manner. Consideration must be given to this evolving scenario over the lifetime of rodents, particularly when selecting the highest dosage for a 2-yr carcinogenicity study.
In the majority of instances, toxicokinetic parameters alone do not provide a definitive rationale to support dosage selection in chronic toxicity studies.
The limitations of toxicokinetic data in this regard are largely related to the fact that the plasma concentration ofdrug may bear little relation to absolute tissue concentration at the critical site of toxicity (1 1, 12) . This is especially true for drugs whose toxicity is related to the generation of reactive intermediates or free radicals, or binding to tissue mac-romolecules, or biochemical interaction with a vital enzyme system. In these cases, the development of toxicity is governed by both the rate of exposure (i.e., the rate at which the local tissue concentration is achieved) and the cumulative exposure over time, since toxicity is the result of disequilibrium between injury and repair occumng over the course of each successive dosing interval throughout the duration of the study. Thus, the amount of the dose to which the body is exposed over time and the amount of the dose subject to metabolic processing are the key determinants of toxicity in chronic toxicity studies (9) . In this connection, measurement of drug concentration in plasma following a single dose may not be a good guide to dosage selection for chronic toxicity studies. Rather, steady-state toxicokinetics should be used to assist dosage selection.
The amount ofan oral dose to which an organism is exposed can be calculated if the fraction of the dose absorbed and the fraction that is available systemically are determined. The fraction of an oral dose available Systemically can be quantified by measurement of the drug and related metabolites recovered in urine in the case of drugs which are eliminated completely by this route. In the case of drugs not cleared exclusively in urine, the amount recovered in urine represents the minimum fraction of the oral dose absorbed. In the case of drugs that are subject to high first-pass metabolism by the liver, after absorption from the gut, the fraction of the absorbed oral dose thus extracted by the liver is the relevant dose to this organ; concentrations of drug The extent of systemic exposure is dependent on a variety of host factors, the physicochemical nature of the drug (lipophilicity, hydrophilicity) as well as the frequency and route of administration (3, 7) . The extent of binding to plasma protein may be an important factor because it is free drug which gains access to critical cellular and subcellular sites to evoke toxicity (17) . The relationship between AUC, the oral dose administered (Do), the fraction of the dose absorbed (F), and the clearance of the drug (C) is shown by the following equation:
The fraction of the oral dose absorbed and the rate of absorption are determinants of the plasma concentration achieved as well as the total exposure to drug and drug-related products over a given interval of time. However, it is also apparent that the AUC could remain virtually unchanged despite escalation of the oral dose if, simultaneously, the fraction of the oral dose absorbed was decreased. Similarly, the AUC could remain constant, despite a dose-proportional increase in the fraction of the dose absorbed, if a .similar fractional increase in clearance were to occur in relation to each increment of the oral dose. In other words, a true increase in the overall dosage to the animal would not be reflected in a proportional change in the AUC. Such a situation could also arise if the plasma protein binding became saturated for a low clearance drug, thus increasing the free drug concentration available for clearance. Thus, the AUC alone may significantly underestimate the exposure of target organs and tis-sues which are, in the final analysis, the relevant sites of drug exposure.
THE USE AND MIS-USE OF AUC DATA IN

DOSAGE SELECTION
There is no question that the acquisition of toxicokinetic data at the appropriate stage in the sequence of toxicology studies conducted in the course of drug development has ad.ded considerable refinement to the design of toxicology studies and the interpretation of toxicology data. However, it is difficult to prescribe a universal guideline that would state that one measure of drug exposure is more acceptable than another for the purpose of dosage selection. Evidently, a combination of data as well as clinical judgment is required. The purpose of this section is to highlight the pitfalls that may be encountered if the AUC is the sole criterion used for dosage selection, particularly for setting a limit on the highest dosage to be used in a chronic toxicity study. The 4 case scenarios presented in Fig Compounds eliciting toxicity by these mechanisms often do so at plasma concentrations of drug significantly below those observed in humans at therapeutic dosages. The maximum AUC cannot be attained in repeat-dose toxicology studies because overwhelming toxicity is observed at lower dosages. Selection ofthe highest dosage for a toxicology study would be determined solely by toxicity in this case.
E-xaniple B
In Example B, limiting toxicity is observed at the point of inflection, when the AUC reaches a plateau in relation to the oral dosage. 0 Lipophilic compound; reversible mode of action; rapid equilibration between free drug in plasma and tissue site of toxicity. 0 Pharmacologically or biochemically mediated toxicity; primary or secondary mechanism. 0 AUC increases in a proportional fashion with dose up to toxic levels of exposure.
In this case, toxicity may be correlated either with plasma concentration at C, , or with the AUC. Toxicokinetic data should be considered in conjunction with the nature and seventy of the toxic effect($ produced and should be given equal weight with other endpoints for the purpose of dosage selection.
Exaritple C
In Example C, limiting toxicity occurs at a dosage corresponding to some value of the AUC on the nonlinear portion of the curve. The toxic response may increase in seventy with increasing dosage without an apparent increase in the AUC.
Physical effects of excessive oral dosage leads to gastrointestinal or excretory organ dysfunction. Saturation of protein binding; clearance increases proportionally with increase in free fraction of drug; increase in amount of drug absorbed not reflected in increased AUC. Saturation of metabolism; secondary metabolites reach toxic tissue concentrations; toxicity may occur at local site of metabolite production. Saturation of tissue receptors resulting in functional decompensation of target organ.
Pharmacological activity of partial agonist at supramaximal tissue concentrations.
The disadvantage ofutilizing either limiting toxicity or the AUC as the sole determinant for high dosage selection is well illustrated by this example. Effective systemic exposure may be grossly underestimated by AUC total, which may not reflect the exposure to unbound drug at the toxic dosage. The concentration of unbound drug may be increasing linearly with dose even though AUC total appears to have plateaued. Additionally, increased clearance, occurring in parallel with increasing dosage, would yield a constant value of AUC total despite a progressive increase in absorption and the amount of the oral dosage to which the animal is effectively exposed. It may be important to understand these mechanisms in such cases, before a decision is made to escalate the dosage to the maximum tolerated limit.
Es-ainple D
In Example D, no toxicity and no increase in the AUC is evident with increasing dosage. 0 Nontoxic drug, or failure of test species to metabolize the administered drug to its active form. 0 Saturation of absorption. 0 Small fractional increases in absorption with increasing dose not discernable as increase in AUC total.
Although the absence of toxicity is a relatively uncommon experience in drug development, this scenario most likely reflects the fact that exposure is limited by absorption. In this situation it is reasonable to limit the highest dosage to that which produces no additional increment in AUC. The alternative is to attempt -a different route of administration to circumvent the bamer to intestinal absorption or to select an alternative species that would permit increased systemic exposure and characterization of toxicity.
TOXICOKINETIC CONSIDERATIONS IN DOSAGE SELECTION-CASE STUDIES
In thisSection, we present data obtained in the course of developing 3 chemically unrelated drugs, each with a unique mechanism of action and intended for different therapeutic indications. The objective is to illustrate how judicious use of toxicokin-.etic data can contribute to study design, dosage selection, and the interpretation of toxicology data.
Soijvouiid A
Compound A was administered orally, by gavage, to male and female rats to support the initial phases of clinical development. The plasma concentration of parent drug at steady state in male rats, over 24 hr, after exposure to dosages ranging from 15 to 200 mg/kg, is shown in Fig. 3 . The data indicate that the compound, though efficiently absorbed, was subject to significant first-pass metabolism by the liver evidenced by a disproportional increase in exposure relative to dose. Thus, systemic exposure after an oral dose of 15 mg/kg was low and shortlasting; the parent compound was cleared completely from the plasma within 2 hr of dosing. A dose of 60 mg/kg resulted in a C, , of 940 ng/ml; however, the compound was cleared from the plasma almost completely by 8 hr after dosing and was completely eliminated from the plasma by 24 hr after all dosages up to 200 mg/kg. Toxicity was observed upon repeated dosing at 150 and 200 mg/kg/day in male and female rats, respectively.
The pharmacokinetic profile of Compound A in human volunteers at steady state in Fig. 4 was obtained by computer modeling of data generated after a single 50-mg dose. The model predicted that, after a therapeutic dose of 10 mg, the plasma concentration of the parent compound would range from 60 ng/ml at C, , , to 30 ng/ml at Cmin, yielding an AUC, 24 of 1,100 ng-hdml. This modeled pharmacoki- netic profile at steady state was confirmed in a subsequent repeat-dose clinical study.
Based on the foregoing evidence, we concluded that oral dosing by gavage would not provide optimal exposure for a carcinogenicity study in rats. We decided, therefore, to assess exposure to Compound A in rats receiving drug as an admixture in the diet. The plasma concentration profiles of Compound A, over 24 hr, in rats receiving 50 or 200 mgkg in the diet (Fig. 5 ) dcmonstrate that the maximum plasma concentrations are achieved between 10 and 12 hr after the onset of the 12-hr dark phase, when the rats consumed most of their daily intake of food. The plasma concentration at 50 mg/kg was maintained at close to a maximum of 155 ng/ml for more than 8 hr and remained above 30 ng/ml (the human Cmin at steady state) for up to 14 hr. Although 50 mg/kg given in the diet to rats yielded lower multiples of the human AUC and C,,,, compared to 60 mg/kg by gavage, sustained exposure for up to 14 hr per day, at plasma concentrations of drug approximately 2.5 times the C, , at steady state in humans, offsets the higher levels of exposure achieved by 60 mg/kg given by gavage ( Table I) . The low dose of 25 mdkg was estimated to achieve in,e&uivalent but more sustained exposure to Compound A at C, , compared to 15 mg/kg by gavage.
However, the AUC at 25 mg/kg in the diet was estimated to be 3 times the AUC after 15 mg/kg by gavage, slightly less than the AUC in humans after a 10-mg dose. As was evident after gavage dosing, exposure was disproportional to dosage at 200 mg/ kg when compared to exposure at lower dosages (Table I) . Toxicity was again evident at 200 mg/kg even though AUC and C, , values resulting from dietary administration were reduced significantly, (Table I ). This suggested that exposure sustained above a critical threshold was a factor in the toxicity caused by Compound A, providing further justification for administering the drug in diet. These data supported the rationale for electing to administer Compound A in the diet to rats in a carcinogenicity study. It was anticipated that a high dosage of 100 mg/kg would not compromise survival of rats in the 2-yr carcinogenicity study and was likely to yield maximal exposure to drug in plasma, respectively, 10-and 15-fold the steadystate AUC and C, , achieved in humans after a 10mg dose, once daily (Table I) .
Coinpound B
Compound B was well tolerated by the rat and dog at oral dosages up to 1,000 mg/kg. Approximately 8% of an oral dose of 100 mg/kg to rats was recovered in the bile. There was negligible recovery of the drug in urine and very little metabolism, as 97% of the oral dose recovered in the bile was unchanged parent compound. Hepatic clearance was greater in both rats and dogs than in humans (Table  11 ). Blood clearance in the dog was approximately equal to hepatic blood flow. The compound was highly protein-bound in plasma; however, the concentration of unbound drug in dogs at C,,, was approximately 12-fold greater than the concentration of unbound drug in rats or humans ( Table 11 ). The fraction of the oral dose absorbed declined signifi;, cantly with increasing dosage in both the rat a d dog (Table 111 ). The fraction of the oral dosage (350 fraction (9'0) 1.90 -
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1.60 mg once daily) absorbed in humans was 24%, whereas in rats and dogs, respectively, only 2 and 6% of the 1,000 mg/kg dosage was absorbed. Thus, the amount of the oral dosage absorbed in humans, rats, and dogs was 1.2, 20, and 60 mg/kg, respectively, at the highest dosages employed. Systemic bioavailability of an oral dosage of 350 mg in humans was 20%, whereas in rats and dogs receiving a dosage of 1,000 mg/kg, systemic bioavailability was approximately 1%. Thus, the effective systemic dosage in humans, rats, and dogs was 1.0, 8.8, and 10.8 mg/ kg, respectively, at the highest dosages employed. On examination of the plasma concentration data obtained in rats, dogs, and humans, it was evident that the therapeutic human dose of 5 mg/kg yielded AUC and C, , , values which were similar to the corresponding values in ihe dog receiving an oral dose of 1,000 mg/kg (Table IV) . Both the AUC and C,,, values in rats receiving 1,000 mg/kg were less than the corresponding values in humans given an oral dose of 5 mg/kg (Table IV) . However, consideration of the amount of the oral dose (mg/kg) to which the 3 species are exposed shows that the effective systemic dose in the rat and dog is 8to 10fold greaier than the equivalent systemic dose in humans (Table IV) . Systemic exposure of the dog to unbound drug in plasma is greater by a further factor of 8 compared to humans (AUC = 65.5 pg. min/ml in dog, 8 pg-rninlml in human). Systemic exposure underestimates exposure of the liver by a factor of 2-5 in the rat and dog, respectively. It is evident from this case that the oral dosage grossly overestimates exposure in animals compared to humans. It is equally clear that comparison of the AUC and C,,, across the 3 species grossly underestimates the effective (total body) exposure to the oral dosage in the 2 animal species compared to humans. Exposure to Compound B was limited by absorption at a dosage of 1,000 mg/kg, since there was not a further increase in the AUC with increasing dosage. On this evidence, and on the basis of the multiples of effective exposure to the oral dose achieved in rats and dogs compared to humans, we decided that 1,000 mg/kg should be the highest dosage to be administered by gavage in 6-mo toxicology studies.
Coiiipoiiiid C
The primary action of Compound C is to suppress the production of gastric acid, which, secondarily, induces secretion of gastrin by cells of the pyloric antrum. Typically, the human therapeutic dose of 40 mg produced an AUC ranging from 127 to 333 pg-min/ml. It is well established that persistent elevation of serum gastrin is causally associated with hyperplasia and neoplasia of enterochromaffin cells in the fundic mucosa of the rat stomach. In female rats administered dosages of 5 , 50, or 300 mg/kg, orally, by gavage, the resulting systemic exposure to drug expressed as the AUC was linear in relation to dosage (Fig. 6 ). Compound C was not detectable in the plasma of rats 4 hr after an oral dose of 5 mg/kg (Fig. 6) .
In advance of selecting dosages for a 2-yr carcinogenicity study, we analyzed serum gastrin concentrations over 24 hr in female rats dosed orally, by gavage, with 0.5, 1.0, or 3 mg/kg of Compound C. Dosages of 0.5 or 1 mg/kg-did not elevate serum gastrin concentration compared to controls (Fig. 7) , whereas a dosage of 3 mg/kg caused a 3-4-fold increase in serum gastrin concentration, which was sustained for up to 16 hr after dosing. Thereafter, serum gastrin returned to control values at 24 hr ( Fig. 7 ). In a subsequent study, we measured serum gastrin concentration 24 hr after dosing with dosages ranging from 0.5 to 500 mg/kg. Serum gastrin was elevated'significantly above controls at dosages of 0:s mg/kg or greater (Fig. 8) . No effect was apparent at-0.5 mg/kg. The effect was maximal at 320 mg/kg with no further increase at 500 mg/kg (Fig. 8 ). Since Compound C was virtually undetectable in plasma 8 hr after an oral dose of 5 mg/kg (Fig. 6) , it is evident thatdhe persistent elevation of serum gastrin is not dii-ecdy related to the sustained plasma concentration of drug. With the knowledge that persistent elevation of serum gastrin for 24 hr is associated with the induction of carcinoid tumors, we selected 0.5 mg/kg as the low dose for the 2-yr study, anticipating that this should be a no-effect dose. To further define dose-response relationships in the carcinogenicity study at the lower end of the dose range, we elected to include an additional low dose of 5 mg/kg/day. The middle dose was 50 mg/kg. Because an oral dosage of 300 mg/kg had not been well tol- erated by rats in a previous 12-mo study, we selected 200 mg/kg as the highest dosage in the 2-yr study.
The incidence of carcinoid tumors in female rats of the 2-yr study (70 rats per group) is presented in Fig. 9 . As expected, there was a dose-related incidence of rats with tumors at dosages of 5 , 50, and 200 mg/kg/day, a response that mirrors the effect on serum gastrin. One rat in the group receiving 0.5 mg/kg/day for 2 yr developed a carcinoid tumor of the stomach. This was attributed to individual variability in the pharmacodynamic response to Compound C, since the ED,, for gastric acid suppression in the rat ranges from 0.5 to 0.8 mg/kg.
The lowest dosage of Compound C for a 2-yr study was selected on the basis of the pharmacodynamic dose response, not on the basis of concentrations of drug achieved in the plasma compared to humans. The high dose was limited exclusively by toxicity in this case. Although toxicokinetic data did not make a substantive contribution to dosage selection for the carcinogenicity study, it was important to know that exposure to Compound C in the rat (AUC or Cma) relative to humans could not be used for assessing the safety of the drug in human patients, since the concentration of drug in plasma was not directly related to the induction ofcarcinoid tumors. Moreover, the AUC at steady state in rats receiving a dosage of 5 mg/kg was slightly less than the AUC in humans given a therapeutic dosage of 40 mg daily.
CONCLUSIONS
Practical experience of drug development and an appreciation of toxicokinetic principles make it abundantly clear that dosage selection (high or low) in toxicology studies of new therapeutic agents cannot be based on a standardized formula. Consid- eration must be given to a compound's pharmacological mode of action, its physicochemical properties, its potency in each of the test animal species, and its ADME profile. The route of administration and the nature of the formulation to be used in humans, as well as the therapeutic indication for which the compound is intended, also must influence dosage selection in toxicology studies.
Although the toxic potential of drugs and chemicals can be assessed in relative terms according to the response of different animal species to an empirical dose, the significance of the effects observed cannot be evaluated fully in the context of human safety without knowledge of exposure, both qualitative and quantitative. However, it is important to keep in mind that toxicokinetic data alone are insufficient to determine the suitability of dosages selected for a toxicology study. Data from a variety of differeqt sources must be incorporated into the decision-making process so that the results obtained from toxicology studies can be utilized meaningfully in the assessment of potential hazard to human patients (16) .
It is inappropriate to use a single measure of exposure to drug in plasma (e.g., C, , , or AUC) to limit the highest dosage in a toxicology study. Consideration of the fraction of the dose absorbed and the fracti6n of the dQse to which the animal is exposed systemically, as well as the extent of protein binding, are useful additional measurements. It may be appropriate, within reasonable limits, to evoke nonlinear kinetics (Le., to saturate metabolism and/or elimination) at the highest dosage in order to characterize fully the toxic potential of the drug under investigation in animal studies prior to Phase I. However, extrapolation of toxic effect and exposure data derived under these conditions from animals to humans for safety assessment of drugs intended TOXICOLOGIC PATHOLOGY for chronic use in patients is likely to be unwarranted.
It is also inappropriate to use pathological injury to a major organ as the predominant criterion for selecting the highest dosage to be used in a toxicology study. The pharmacologic and pathologic effects that may result from excessively high dosages should be moderated, for these can lead to atypical disposition ofdrug in the body which, in turn, generates spurious toxicity of little relevance to humans. Major organ systems, whether primary targets for a drug's principal action or key to its mctabolism and elimination, should preserve their functions within reasonable physiological boundaries. If the highest dosage used in a toxicology study results in abnormal organ function which may, by primary or secondary mechanisms, lead to tissue injury, the effect must be short-lasting, thereby allowing for rapid recovery to occur after each dose. The induction of repeated tissue injury in chronic toxicology studies is not consistent with the purpose behind the development of human therapeutic agents that will be prescribed under medical supervision.
It is quite obvious that judicious selection of dosages at the beginning of a toxicology study governs the outcome of the study, the quality of the data generated, and, ultimately, the value of the study for the purposes of safety assessment. Most of the debate concerning dosage selection in toxicology studies is centered on which criteria should be applied to limit the highest dosage. As a consequence, and somewhat by default, insufficient attention has been given to selection of the lower dosages in toxicology studies. This is essential to achieve adequate dose (exposure)-response data. Effects seen at these lower dosages in animals may be the most critical elements in assessing a compound's potential to produce adverse effects in humans. Careful selection of dosages at the lower end of the dose range is vital to meet this important objective. Particular attention should be given to surrogate markers of biologic, hormonal, pharmacologic, and toxicologic effects at the lower dosages, and these should be correlated yith relevant indicators of exposure. In this way, different biologic and toxicologic responses can each be related individually to a quantifiable' index of exposure. A more precise understanding of exposure4fect relationships in the test animal species at lower dosages greatly enhances our ability to assess the potential for adverse effects in human patients receiving the drug at therapeutic dosages.
In recent years it has become common practice to incorporate toxicokinetic data into the process of hazard assessment of human pharmaceuticals. While this certainly adds precision to the process, it is unfortunate that too narrow a focus has been placed on comparing plasma concentration data across species. Thus, frequently, multiples of c,,, or the AUC in animals relative to humans are quoted as safety factors, without due consideration being given to species-specific differences in pharmacological responsiveness, or susceptibility to particular toxic mechanisms, or metabolism (5) . Often, such comparisons based solely on parent-drug plasma concentration data do not take account of the total amount of the dosage received by the animal in a toxicology study as compared to the human receiving a therapeutic dosage. However, comparison of plasma concentration data within a given species can be meaningful if the toxicity or adverse event is truly related to exposure to drug in the pIasma; this provides a reliable estimate of therapeutic index. For example, multiples of the AUC6r C, , at toxic dosages versus corresponding values obtained at pharmacologically active dosages in the same species provide a useful measure of a drug's safety in the rat, dog, or monkey. If the concentration of drug in plasma is not relevant to the mechanism of toxicity or adverse effect, or if differences in species sensitivity to a drug's action are not taken into account, then multiples of the AUC or C,,, may grossly underestimate or overestimate a drug's intrinsic toxicity. There is no doubt that toxicokinetic data add an important dimension to the design and interpretation of toxicology studies. However, the full value oftoxicokinetic data in dosage selection, study design, and risk assessment can only be realized if they are properly integrated with other data ob-. tained in animal toxicology studies and human clinical studies.
